People with dementia are often excluded from clinical study and very little attention has been given to sex-or genderbased differences in medication use. It is recognized that men and women have differences in pharmacokinetics and likely seek treatment for different medical conditions. These sex-related differences likely affect medication doses or profiles, but these differences are not well understood and no studies to date tackle the differences in drug use in older adults with dementia.
Introduction
Polypharmacy is a well-recognized concern for older adults. 1, 2 Worldwide estimates of polypharmacy vary by country, sex, age, and accepted definition. [1] [2] [3] [4] [5] [6] At present, there is not a universally accepted definition of polypharmacy. Polypharmacy was investigated in a recent systematic review 6 where authors identified 138 different definitions. Polypharmacy definitions included numerical definitions determined by the number of drugs used, descriptive definitions which considered co-prescribing of multiple medications, and appropriate or inappropriate polypharmacy which examined drugs used even though they are recommended to be avoided, according to consensus-based tools such as Beers criteria 7 or the medication inappropriateness index. 8 Regardless of definition, polypharmacy is a problem for older adults. In the United States, 30% of adults aged 65 years and older are taking six or more drugs daily, 3 and in Canada, estimates suggest 63% of seniors are taking more than 5 medications and 30% of those older than 85 years are taking more than 10 medications. 9 Dementia increases the risk for polypharmacy 5 with pharmacotherapy being an exceedingly common treatment for the behavioral and psychological symptoms of dementia (BPSD). [10] [11] [12] This is despite the knowledge that drug therapy has limited beneficial effect on BPSD. 11, 13 In general, studies enroll younger populations 14 and rarely include those with frailty or complex comorbidities with the resulting complex medication regimen. [15] [16] [17] Extrapolating from younger populations to older individuals or those with dementia is not ideal given pharmacokinetic and pharmacodynamic differences in medication response between older adults and their younger and healthier counterparts. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Pharmacokinetic changes that need to be considered include the following: drug elimination slowing with age due to decreasing kidney function, 31, 32 changes in body composition with age which may significantly influence drug distribution and effect, 33 and decreasing cytochrome P450 enzyme content, 21 which alters drug metabolism. In addition, characteristics of the blood-brain barrier change 34 which alters drug introduction to the central nervous system. This is especially true for those with dementia. 35 These changes associated with aging may unpredictably influence serum drug concentrations, drug effect, and toxicity. Even so, age-related changes in drug effect are recognized by clinicians in many guidelines and tools to help guide clinical decision-making for drug use for older adults. 7, 36 Differences in drug pharmacokinetics and pharmacodynamics are not limited to the effect of aging; there are also differences in drug metabolism between males and females. These poorly understood sex-related differences are compounded by the age-related changes and include differences in hepatic metabolism, 21, [37] [38] [39] [40] [41] [42] [43] [44] intestinal metabolism, 40 drug distribution, 42 and renal clearance. 43 These sex differences have been identified but have not been well delineated and their clinical significance is thus not well understood.
The lived experience of dementia also differs between men and women. Older women are more likely to develop dementia, with 38% greater risk than older men. 45 In North American populations, women with dementia live on average 6 months longer than men with dementia, and women with Alzheimer's Disease (AD) are more likely to live in a nursing home than men with AD. In addition, North American women with dementia spend 94% of their time with dementia in a nursing home, whereas men spend closer to 60% of their time with the disease in nursing homes. 45 Some of these differences likely relate to sex (biological differences, e.g. metabolism), while others relate to gender (social roles, e.g. caregiving roles and longevity in relation to a caregiving spouse). 46 Gender roles may also lead to men and women seeking treatment for different conditions and may influence prescribing practices, with drug selection being influenced by physician gender biases. 47, 48 While investigations into gender differences in prescribing have not specifically focused on older adults with dementia, there is no reason to believe that these principles do not apply. Indeed, these differences may be even more important to understand in older adults with dementia due to their susceptibility to adverse drug reactions. 49 To date, randomized controlled trials designed to evaluate drug use for older adults with dementia have not investigated sex differences sufficiently to help guide practice. We can likely assume that drugs that are temporally associated with improvements in BPSD or improvements in monitoring parameters of optimal health (such as blood pressure, heart rate, or cognition) are continued, whereas therapies that do not seem to be working are discontinued. This leads to the hypothesis that due to gender and sex differences in medication prescription, use, and response, women and men with dementia will end up on different drug profiles. This is expected to be exacerbated by the differences in comorbidity expression in men and women. Comorbidity, frailty, and cognitive impairment will mean that most of older adults with dementia will be taking more than five medications daily and this polypharmacy profile may differ between men and women based on the many sex and gender differences discussed.
This objective of this scoping review was to understand differences in polypharmacy as determined by medication use including the number of medications or concomitant medications used by older men and women with dementia, with the aim of informing recommendations for research and guiding initiatives to improve drug use.
Methods
A systematic review was not possible as there were no studies designed with a primary objective to explore sex or gender differences in drug use in older adults with dementia. The scoping review methodology was selected for this investigation due to the ability of this approach to present a general overview of a topic area while identifying gaps in the literature base. 50, 51 Arksey and O'Malley 50 have a five-stage framework and this approach guided the present review.
Stage 1: identify the research question
What is the relationship between sex or gender and polypharmacy in older adults with dementia?
Stage 2: identify relevant studies
A search of each of the databases Medline, Embase, Web of Science, CINAHL, and ProQuest was conducted in January 2016 to identify all published research that commented on drug use in people with dementia. Each database was searched from inception to 1 January 2016. The only limit applied to the search was that the article had to be available in English.
Searches were completed for each of three concepts independently, and then the three searches were combined. The search terms included (1) Sex, gender, masculinity, femininity, machismo; (2) Polypharmacy, deprescriptions, drug combinations, drug therapy combination, polypragmasy, inappropriate prescribing, mulitmedication, deprescribing; (3) Dementia, cognitive impairment. The search strategy is shown in Figure 1 .
Stage 3: study selection
All identified abstracts were reviewed by two reviewers with the aid of Distiller SR software © . Abstracts were selected for full-text review if they (1) were in English, (2) reported on an original study with human subjects among whom at least a subset had cognitive impairment, and (3) reported on older adults 65 years of age or older. Articles identified from the abstract review were reviewed by two reviewers. Articles were included in the final scoping review if they (1) were in English, (2) reported on original research, (3) if the subjects (or an identifiable subset) were 65 years of age or older, (4) if there was a clear population with dementia, (5) if those with dementia were subdivided into males and females, and (6) if some medication-specific information was provided by sex or gender. Conflicts at either stage of review were resolved via consensus reached after discussion focused on the relevant selection criteria.
While study quality is not typically a component of a scoping review, quality was assessed using the National Institutes of Health (NIH) sponsored National Heart, Lung, and Blood Institute's Quality Assessment for Case-Control Studies or Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies as appropriate 52 (and rated as good, fair, or poor) or the Cochrane Collaboration's tool for assessing risk of bias for randomized controlled trials 53 (and rated as low or high risk). The quality of studies was subjectively rated by the two reviewers and based on the criteria in the tools. This was done to explore the merits of the included studies in an effort to identify the level of attention to sex-or gender-specific findings regarding polypharmacy but did not impact decisions regarding inclusion/exclusion of articles in the scoping review process.
Stage 4: charting the data
Data are charted in a summary table. Details of the studies that were of interest for the review included study design, study purpose/objective, subject population, analytic model, key findings, and an appraisal of evidence quality.
Stage 5: collating, summarizing, and reporting the results
Study findings and characteristics were considered with respect to what they revealed about the role of sex or gender on polypharmacy in older adults with dementia by each of the study authors. This led to the summary of findings and a description of the gaps in the existing literature.
Results
In total, 231 unique abstracts were identified for review. In addition to the search strategy, Figure 1 shows the process followed for article selection. Only 140 abstracts met inclusion criteria and went on to full-text review. Of the 140 fulltext articles reviewed, 12 were appropriate for inclusion in the final review. A summary of the 12 included papers is provided in Table 1 .
Findings for men
In general, the included studies reported increased use of antipsychotics and cholinesterase inhibitors among men. In a Finnish cohort of community-dwelling seniors with dementia, using more than one antipsychotic medication at a time was associated with male sex. 54 Men with dementia and no diagnosis of schizophrenia who were inpatients in acute care hospitals in England had a 10% increased use of antipsychotics. 55 Nursing home dwelling men near end of life were taking 1.36 times as many medications per day as women, and these men were more likely to be using a medication considered to be potentially inappropriate by the study authors at end of life. 57 In a longitudinal cohort comprising people with cognitive impairment across 59 sites in the United States and Canada, cholinesterase inhibitor use was more common in men (93.8%) compared to women (78.4%) (p = 0.002). 60 Logistic regression showed that male sex (odds ratio (OR) = 3.61; 95% confidence interval (CI) = 1.35-9.66) was associated with increased use of cholinesterase inhibitor treatment. 60 Men received more lipid-lowering therapy than women. 63 None of the studies reported on gender-specific findings for men.
Findings for women
The review showed that women were generally exposed to more psychotropic medication. In a German study of community-dwelling people with dementia, female sex was associated with an increased risk of inappropriate medication use (OR = 10.36, 95% CI = 1.28-83.87) according to the PRISCUS list. 56 In community-dwelling seniors with dementia in France, female sex was associated with increased odds of PIM use according to the LaRoche list (OR = 1.5; 95% CI = 1.1-2.2). 59 The second study from France analyzing the cohort of the first 5000 subjects initiated on tacrine, the first drug available for dementia treatment and a centrally acting anticholinesterase and indirect cholinergic agonist, considered their medication use 3 months prior to enrollment in the cohort showed that benzodiazepine users were more likely to be female (p < 0.001). 61 Female residents of Dutch nursing homes had increased use of antidepressant medications in both models explored (OR = 1.44 and 1.49). The first model adjusted for Neuropsychiatric Inventory Nursing Home symptoms, and the second model adjusted for the Cohen Mansfield Agitation Inventory symptoms. 62 In a group of subjects with confirmed dementia from Stockholm's Kungsholmen district born in or before 1912, there was a statistically significant (p < 0.05) association between female sex and use of a number of medication classes: hypnotics and sedatives (OR = 1.70), anxiolytics (1.90), potassium (1.43), minor analgesics and antipyretics (1.42), thiazides (1.82), nonsteroidal anti-inflammatory drugs (NSAIDs, 2.32), thyroid preparations (5.12), centrally acting muscle relaxants (2.02), multivitamins (4.95), and psychotropic drugs (1.87). 65 None of the studies reported on gender-specific findings for women.
General sex-specific findings
In community-dwelling seniors in the United States with dementia, use of a drug with anticholinergic activity was not significantly related to sex (χ 2 = 1.07; p = 0.300). 58 In older community-dwelling adults living alone who were followed in the Swedish Alzheimer's Treatment Study, no significant sex differences were observed in drug therapy at the initiation of cholinesterase inhibitor therapy. 63 Patients receiving cholinesterase inhibitors in the preceding year were more likely to receive anticholinergic spasmolytics (OR = 5.6; 95% CI = 3.7-8.5), and this drug-drug combination did not differ between sexes. 64 General gender-specific findings Surprisingly, none of the studies reported on gender-specific findings.
Discussion
This scoping review identified 12 papers that provided insight into sex-related differences in polypharmacy in those with dementia; however, none of the papers made any comment on gender-related differences. The identified papers highlight several findings. Most notably, among communitydwellers, women were more likely to receive PIMs, 56, 59 whereas among residents of nursing homes, men received more PIMs. 57 Men with dementia in nursing homes were taking more medications overall 57 and in particular, more antipsychotics. 54, 55 Men in the community used more cholinesterase inhibitors than women. 60 Women with dementia used more psychotropic medications than men. [61] [62] [63] 65 The existence of the drug-drug interaction of a cholinesterase inhibitor combined with an anticholinergic medication did not differ by sex. 58, 64 Antipsychotic use was higher among hospitalized and institutionalized men. Taipale et al. 54 showed that using more than one antipsychotic was more common in men with dementia, and Stephens et al. 55 found that male sex was associated with a 10% increase in the likelihood of antipsychotic use in hospitalized individuals with dementia. This is not be surprising, given concerns that men may be more prone to experiencing violent responsive behaviors and using antipsychotics is a culturally acceptable method to attempt to reduce BPSD despite a lack of scientific data supporting their use. 66 It follows then that in nursing home patients with advanced dementia, men are more likely to take a PIM, 57 this is likely driven by the increased use of the antipsychotics 55 in this population. This is contrasted with the findings of Wattmo et al., 63 who suggest that community-dwelling women with dementia use more antipsychotics. It is conceivable that increased antipsychotic use by community-dwelling women with dementia is simply reflective of the increased use of psychotropic medications by women with dementia in general. 65 Women with dementia's increased use of psychotropic medication is driven by an increased use of antidepressants, 62, 63 hypnotics, sedatives, and anxiolytics. 61, 63 Antidepressants reach higher serum concentrations in women 67 which may be mediated by gastric pH, which is higher in females, and may increase absorption of medications whose active ingredients possess basic functional groups such as many antidepressants. 67 It is worth questioning whether the reduced use of antidepressants in men with dementia is due to their reduced effect driven by lower serum concentrations being achieved.
In one study of community-dwelling seniors with AD, men were more likely to be taking a cholinesterase inhibitor. 60 This is a surprising finding as women with AD in the community are otherwise more likely to use psychoactive medication. The lower use of cholinesterase inhibitors among women might be related to their lower body weight and a reluctance by clinicians to initiate this therapy with its attendant risk of gastrointestinal upset and weight loss. It is also a consideration that women likely achieve higher serum concentrations of cholinesterase inhibitors due to their higher gastric pH, 67 that they experience the adverse effects at a greater rate, and thus are unable to tolerate and continue treatment. However, the finding that men with dementia use more lipid-lowering therapies suggests that cardiac comorbidities are more common in community-dwelling men with dementia 63 but may also reflect known differences in cardiovascular comorbidity identification and treatment between men and women in the general population. 68 Urinary incontinence is a well-known side-effect of cholinesterase inhibitors. Despite the antagonistic nature of using an anticholinergic medication to control urinary incontinence in an individual on a cholinesterase inhibitor, this strategy is attempted by some clinicians. This drug combination is generally not considered to be appropriate due to the side-effect profile of bladder antispasmolytic agents and because of the counter-productive drug interaction whereby they offset the activity of the cholinesterase inhibitor. No sex differences have been identified in the use of this combination of drugs. 58, 64 Our most startling finding was the lack of research on the topic of sex differences in drug use in older adults with dementia. None of the studies we identified were designed to focus on sex-related differences in drug use in older adults with dementia. Reported sex differences are not the primary objective of any of the studies but instead represent secondary findings. When sex differences were presented, the majority of studies commented only on the use of central nervous system active agents, but we know from prior work that frailty and many other social, economic, and healthrelated factors influence outcomes in dementia and should influence overall medication use. The quality of the studies was variable, though the majority of the included trials were agreed to be of good quality according to the National Heart, Lung, and Blood Institute's criteria for observational cohort and cross-sectional studies and case-control studies. 52 Also, no studies made any comment about participant gender or gender-related factors, which prevents any gender-based analysis of findings. Even so, our search strategy was designed to be as broad as possible, inclusive of many definitions of polypharmacy, and the scoping review methodology (as opposed to a systematic review) allowed for more detailed investigation of the existing literature. None of the studies identified were randomized controlled trials. The studies identified were only observational. Certainly, this limits the ability to draw firm conclusions based on this scoping review in isolation, but it does permit us to identify areas that require further study. It is also important to point out that none of the identified studies discussed polypharmacy from the perspective of effect on quality of life such as impact on BPSD, time to admission to nursing home or the lived experience of dementia.
Conclusion
In closing, there are many findings in this scoping review that can help characterize polypharmacy in men and women with dementia. Clinicians should be aware of the tendency toward increased psychotropic medication use and inappropriate medication use in women with dementia; ideally, the goal should be to reduce or eliminate the use of PIM. Clinicians should carefully review men and women's medication lists for anticholinergic drug and cholinesterase inhibitor, drugdrug interaction, and seek to discontinue the anticholinergic agents. This potentially inappropriate drug combination should be kept in mind for both men and women. 58, 64 Antipsychotics continue to be used in populations with dementia. Men and women seem to use antipsychotics to greater extents dependent on their living environment (women in the community and men in long-term care facilities). Antipsychotics are also potentially inappropriate and thus clinicians still need to be vigilant for opportunities to reduce their use. Even though the literature is sparse regarding sex and gender differences in medication use in men and women with dementia, further research and knowledge translation efforts are required to understand how we can build upon and use the knowledge of these differences to improve medication use for individuals with dementia.
Author contributions
S.C.T. is the corresponding author; S.C.T. developed the study methods and completed the initial searches of all databases; S.C.T. was one of the two reviewers; S.C.T. made decisions about study inclusion and drafted the paper; S.C.T. made corrections and approved the final paper. M.R. was the second reviewer; M.R. reviewed all abstracts and all full-text articles; M.R. made decisions about study inclusion, made comments on the draft, and helped prepare the final manuscript; M.R. approved the final paper. M.K.A. was the supervisor of the entire project; M.K.A. provided substantial contributions to conception and design of the study and guidance on development of the study methods; M.K.A. reviewed the draft manuscript and revised it critically for important intellectual content; M.K.A. made corrections, and edited and approved the final paper.
Availability of data and material
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
